Stockreport

Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 [Yahoo! Finance]

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report
PDF 2024 Revenue Forecast : Projected ARCALYST net product revenue of $360 - $380 million, indicating approximately 59% growth at the midpoint. Research and Development : [Read more]